Literature DB >> 8188661

Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells.

M Hengstschläger1, M Knöfler, E W Müllner, E Ogris, E Wintersberger, E Wawra.   

Abstract

We compared the cell cycle regulation of thymidine kinase (TK) after centrifugal elutriation in normal human and mouse cells (primary cells, diploid fibroblasts) with its expression in cells transformed with different DNA tumor viruses. Normal cells showed a rise of TK enzyme activity near the G1/S boundary, which peaked in S phase, and in G2 returned approximately to the level of G1. Conversely, in cells derived from viral transformation, TK activity remained high throughout S and G2 phases, although it was induced to a comparable extent at the onset of DNA replication. In addition, transformed cells exhibited much more enzyme activity during all phases of the cell cycle. The observed differences in expression were due neither to different rates of protein turnover nor to differences in enzyme stability. Enzyme activity was always totally paralleled by the protein level. In all normal cells, the pattern of TK mRNA variation during the cell cycle was similar to that of enzyme activity. In all transformed lines, however, mRNA levels were higher and did not fluctuate throughout the cell cycle. Recently we showed (Ogris et al., 1993) that the E2F binding site present in the TK promoter is a target for trans activation of the TK gene by polyoma virus large T antigen. Using cells expressing this antigen under the control of a hormone-inducible promoter, we were able to switch TK cell cycle expression from the normal to the transformed status. Obviously, DNA tumor viruses suppress transcriptional down-regulation of the endogenous DNA precursor pathway enzyme TK during the eukaryotic cell cycle, maybe to improve conditions for their own replication.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188661

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.

Authors:  J Balzarini; C Zhu; E De Clercq ; M J Pérez-Pérez; C Chamorro; M J Camarasa; A Karlsson
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

Review 2.  Gene therapy in head and neck cancer: a review.

Authors:  E Chisholm; U Bapat; C Chisholm; G Alusi; G Vassaux
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

3.  Effects of CO₂ pneumoperitoneum on the expression of thymidine kinase 1 and Ki67 in colorectal carcinoma cells.

Authors:  Chun-Kang Yang; Shen Guan; Min-Gang Ying
Journal:  Surg Endosc       Date:  2014-05-23       Impact factor: 4.584

4.  Dexamethasone inducible gene expression optimised by glucocorticoid antagonists.

Authors:  W Mikulits; D Chen; E W Müllner
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

5.  Oncolytic vaccinia virotherapy for endometrial cancer.

Authors:  Yu-Ping Liu; Jiahu Wang; Victoria A Avanzato; Jamie N Bakkum-Gamez; Stephen J Russell; John C Bell; Kah-Whye Peng
Journal:  Gynecol Oncol       Date:  2014-01-14       Impact factor: 5.482

6.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Authors:  Padma Sampath; Jun Li; Weizhou Hou; Hannah Chen; David L Bartlett; Steve H Thorne
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

Review 7.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

8.  Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Authors:  Steve H Thorne; Tae-Ho H Hwang; William E O'Gorman; David L Bartlett; Shizuko Sei; Femina Kanji; Christopher Brown; Joel Werier; Jin-Han Cho; Dong-Ewon Lee; Yaohe Wang; John Bell; David H Kirn
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

Review 9.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Authors:  David H Kirn; Steve H Thorne
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

10.  Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

Authors:  J Scott Brockenbrough; Janice K Morihara; Stephen E Hawes; Joshua E Stern; Janet S Rasey; Linda W Wiens; Qinghua Feng; Hubert Vesselle
Journal:  J Histochem Cytochem       Date:  2009-08-03       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.